Because the IR signaling culminates in the activation of the PI3-kinase pathway, and because our data demonstrated potent inhibition of AKT phosphorylation in an IGF-2 replete tumor microenvironment, it is worthwhile to attenuate the signaling in this pathway by targeting the IR alternative splicing in combination with other treatment strategies. The gene discussed is AKT1; the disease is neoplasm.